NKGEN BIOTECH INC. -

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

25 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference

04 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease

28 Dec 2023 16:05:14 By Nasdaq GlobeNewswire

NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

27 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

14 Nov 2023 16:48:03 By Nasdaq GlobeNewswire

NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

26 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

24 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

19 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

17 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

11 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

NKGen Biotech, Inc. Announces Closing of Business Combination

02 Oct 2023 08:00:00 By Nasdaq GlobeNewswire